Menu
Nano24 is a clinical-stage company developing the new generation of steroids; CD24-enriched exosomes, as a therapy for hyper-activation of the immune system.
Nano24 Ltd. was founded in 2020 to commercialize innovative technologies based on years of applied and clinical research in Prof. Arber’s and Dr. Shapira's Lab.
We, at Nano24, believe in advanced science and technology. Recruiting global experts with the most recent scientific discoveries to develop a cutting-edge, robust therapy for cytokine storm syndrome.
Designing the future of medicine requires simplicity, out-of-the-box thinking, and precision.
Let's go beyond what's been done before. We have a game changer!
Nano24 is a clinical-stage company developing the new generation of steroids; CD24-enriched exosomes, as a therapy for hyper-activation of the immune system.
Nano24 Ltd. was founded in 2020 to commercialize innovative technologies based on years of applied and clinical research in Prof. Arber’s and Dr. Shapira's Lab.
We, at Nano24, believe in advanced science and technology. Recruiting global experts with the most recent scientific discoveries to develop a cutting-edge, robust therapy for cytokine storm syndrome.
Designing the future of medicine requires simplicity,
out-of-the-box thinking, and precision.
Let's go beyond what's been done before.
We have a game changer!
CEO at Neopharm Investments
Mr. Moshe has vast experience in the health and pharmaceuticals field as well as the consumer-health product's market. Holds a BA degree in Economics & Accounting from Tel Aviv University. Former General Manager of the Research & Development Fund for TASMC. Mr. Moshe is an industry expert and a member of the company’s management advisory board.
Founder of DTR Consulting and Investments, a Corporate Finance and M&A advisory firm specializing in advising large-scale clients in the Israeli capital market. David has over 25 years of experience in the capital market, heading some of the top underwriting firms in Israel. David has led and managed numerous equity and debt financing and stock issuing. David holds a BA in Statistics and an MBA (magna cum laude) from the Hebrew University in Jerusalem.
Seasoned entrepreneur and investment professional with a successful track record in founding, operating, and leading ventures in the real-estate, food and beverage, finance, and internet spaces. Currently actively investing in the areas of Cyber, Fin-tech, MedTech, and Prop-tech spaces. Ben is an active board member in several tech companies and managing director of Family Office.
Mira has three decades of experience in scientific development as well as in building business strategies in the biotech industry. She Co-founded and led companies from the establishment to acquisitions in cancer immunotherapy.
Director of the Division of Surgery and Chair of the Department of Anesthesiology, Intensive Care and Pain at the Tel Aviv Medical Center, Israel. Chair of the Scientific Committee of the European Society of Anesthesiology (ESA). President of the Israeli Society of Anesthesiologists (ISA), representative for the ISA at the NASC and member of the nomination committee of the ESA. Dr Matot received her M.D at the Hebrew University, Jerusalem, Israel.
Head of the Cyclotron/Radiochemistry unit at Hadassah Hebrew University, Head of Research and Development Division, Hadassah Medical Center; Professor of Nuclear Medicine; Director, Cyclotron Radiochemistry Facility, Human Biology Research Center, Department of Nuclear Medicine. Member of the company’s SAB.
Head of the HIV Outpatient Clinic at the University of Bonn in Germany. Dr. Rockstroh is involved in HIV research on antiretroviral therapy, including new drug classes; Former president of the German AIDS Society. A member of the executive committee of the European AIDS Clinical Society (EACS). Member of the company’s SAB.
Senior Product specialist Cell Biology Drug Discovery, ADME/Tox, Stem & Primary Cells, Cell Therapy. Tim has vast experience in the pharmaceuticals industry from the supplier side and with regards to the development of new therapies. Currently, Tim is part of the division on Thermo-Fisher that provides the company with cell line for product development. Tim consults the company with regards to manufacturing, MCB, tech transfer, and manufacturing upscale aspects.
Joseph D. Grant Professor And Professor Of Microbiology And IMMUNOLOGY and practices at Stanford Hospital and Clinics. In his Academic capacity, he is professor, Medicine - Gastroenterology & Hepatology, Professor, Microbiology & Immunology, Member Bio-X, Member, Maternal & Child Health Research Institute (MCHRI), Faculty Fellow, Stanford ChEM-H, Member, Wu Tsai Neurosciences Institute. Prof Glenn is also Director, Center for Hepatitis and Liver Tissue Engineering (2006 - Present).
Mr. Moshe has vast experience in the health and pharmaceuticals field as well as the consumer-health product's market. Holds a BA degree in Economics & Accounting from Tel Aviv University. Former General Manager of the Research & Development Fund for TASMC. Mr. Moshe is an industry expert and a member of the company’s management advisory board.
Specializes in the treatment of lung and bronchial diseases in adults. Head of Department of interventional pulmonology.
A prominent member of the Israeli venture capital arena, Yossi sits on the boards of Gemini portfolio companies JFrog and Minute Media, and has played a pivotal role in the investment lifecycles of Allot Communications , Saifun Semiconductors, Commtouch, Precise, Ornet Data Communication Technologies, the sale of both Adap.tv, PrimeSense and SAmanage, among other, during his nearly three decades at the fund. Yossi is the chairman of bridges Israel and serves as a member of both the Board of Trustees and the MBA steering Committee in the Academic College of Tel Aviv-Yaffo.
2022 © All rights reserved Nano Med | Wordpress Hosting: Fly Guy - https://fly-guy.club
Prof. Arber is a Professor of medicine and gastroenterology. He is the Yechiel and Helen Lieber Professor for cancer research, serves as the Head of the Health Promotion Center and as the Head of the Integrated Cancer Prevention Center at the Tel-Aviv Sourasky Medical Center. Prof. Arber has extensive experience in clinical trials and technology development and vast network of clinical, scientific and commercial connections worldwide. In 1999, he became the head of the GI Oncology Unit at the Department of Gastroenterology at Tel Aviv Medical Center. In 2002, he established and led the Integrated Cancer Prevention Center (ICPC) at the Tel Aviv Medical Center. In 2010 he became the Director of the Cancer Research Center of Tel Aviv University, and since 2011 he heads the Djerassi-Ellias Oncology Center, both of them at Tel Aviv University. In 2014 he was chosen as the president elect of the Israeli Society of Gastroenterology and became the president in 2015 for a three-year term. Prof. Arber is a member of several international scientific committees at UEGF, ASNEMGE, ESMO-GO, GI-ASCO, OMED, and WGO. He published > 300 papers and received numerous grants and awards
Head of Research Laboratory Health Promotion Center and Integrated Cancer Prevention Center, a leading CD24 lab and R&D center of excellence compliant with OECD principles of GLP. Shapira's expertise includes molecular biology, antibody engineering, protein expression and purification, gene delivery, personalized medicine, animal models, and cell biology. Dr. Shapira has extensive experience in GMP pharmaceutical production and leads the manufacturing of EXO-CD24.
Head of the HIV Outpatient Clinic at the University of Bonn in Germany. Dr. Rockstroh is involved in HIV research on antiretroviral therapy, including new drug classes; Former president of the German AIDS Society. A member of the executive committee of the European AIDS Clinical Society (EACS). Member of the company’s SAB.
Senior Product specialist Cell Biology Drug Discovery, ADME/Tox, Stem & Primary Cells, Cell Therapy. Tim has vast experience in the pharmaceuticals industry from the supplier side and with regards to the development of new therapies. Currently, Tim is part of the division on Thermo-Fisher that provides the company with cell line for product development. Tim consults the company with regards to manufacturing, MCB, tech transfer, and manufacturing upscale aspects.
Joseph D. Grant Professor And Professor Of Microbiology And IMMUNOLOGY and practices at Stanford Hospital and Clinics. In his Academic capacity, he is professor, Medicine - Gastroenterology & Hepatology, Professor, Microbiology & Immunology, Member Bio-X, Member, Maternal & Child Health Research Institute (MCHRI), Faculty Fellow, Stanford ChEM-H, Member, Wu Tsai Neurosciences Institute. Prof Glenn is also Director, Center for Hepatitis and Liver Tissue Engineering (2006 - Present).
Mr. Moshe has vast experience in the health and pharmaceuticals field as well as the consumer-health product's market. Holds a BA degree in Economics & Accounting from Tel Aviv University. Former General Manager of the Research & Development Fund for TASMC. Mr. Moshe is an industry expert and a member of the company’s management advisory board.
Specializes in the treatment of lung and bronchial diseases in adults. Head of Department of interventional pulmonology.
A prominent member of the Israeli venture capital arena, Yossi sits on the boards of Gemini portfolio companies JFrog and Minute Media, and has played a pivotal role in the investment lifecycles of Allot Communications , Saifun Semiconductors, Commtouch, Precise, Ornet Data Communication Technologies, the sale of both Adap.tv, PrimeSense and SAmanage, among other, during his nearly three decades at the fund. Yossi is the chairman of bridges Israel and serves as a member of both the Board of Trustees and the MBA steering Committee in the Academic College of Tel Aviv-Yaffo.
Mr. Moshe has vast experience in the health and pharmaceuticals field as well as the consumer-health product's market. Holds a BA degree in Economics & Accounting from Tel Aviv University. Former General Manager of the Research & Development Fund for TASMC. Mr. Moshe is an industry expert and a member of the company’s management advisory board.
Founder of DTR Consulting and Investments, a Corporate Finance and M&A advisory firm specializing in advising large-scale clients in the Israeli capital market. David has over 25 years of experience in the capital market, heading some of the top underwriting firms in Israel. David has led and managed numerous equity and debt financing and stock issuing. David holds a BA in Statistics and an MBA (magna cum laude) from the Hebrew University in Jerusalem.
Seasoned entrepreneur and investment professional with a successful track record in founding, operating, and leading ventures in the real-estate, food and beverage, finance, and internet spaces. Currently actively investing in the areas of Cyber, Fin-tech, MedTech, and Prop-tech spaces. Ben is an active board member in several tech companies and managing director of Family Office.
Mira has three decades of experience in scientific development as well as in building business strategies in the biotech industry. She Co-founded and led companies from the establishment to acquisitions in cancer immunotherapy.
Director of the Division of Surgery and Chair of the Department of Anesthesiology, Intensive Care and Pain at the Tel Aviv Medical Center, Israel. Chair of the Scientific Committee of the European Society of Anesthesiology (ESA). President of the Israeli Society of Anesthesiologists (ISA), representative for the ISA at the NASC and member of the nomination committee of the ESA. Dr Matot received her M.D at the Hebrew University, Jerusalem, Israel.
Head of the Cyclotron/Radiochemistry unit at Hadassah Hebrew University, Head of Research and Development Division, Hadassah Medical Center; Professor of Nuclear Medicine; Director, Cyclotron Radiochemistry Facility, Human Biology Research Center, Department of Nuclear Medicine. Member of the company’s SAB.
